Search

Your search keyword '"Prausnitz, Mark R."' showing total 1,157 results
Start Over Author "Prausnitz, Mark R."
1,157 results on '"Prausnitz, Mark R."'

3. A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial

Author

Adigweme, Ikechukwu, Yisa, Mohammed, Ooko, Michael, Akpalu, Edem, Bruce, Andrew, Donkor, Simon, Jarju, Lamin B, Danso, Baba, Mendy, Anthony, Jeffries, David, Segonds-Pichon, Anne, Njie, Abdoulie, Crooke, Stephen, El-Badry, Elina, Johnstone, Hilary, Royals, Michael, Goodson, James L, Prausnitz, Mark R, McAllister, Devin V, Rota, Paul A, Henry, Sebastien, and Clarke, Ed

Published
2024
Full Text
View/download PDF

6. How Chemical Engineering Students Have Changed over Two Decades: A Perspective from Georgia Tech

Author

Prausnitz, Mark R., Cuba-Torres, Christian M., Liu, Nian, and Lee, Yunki

Abstract

To characterize the professional interests, motivations, aspirations and demographics of chemical engineering (CHE) students, we surveyed almost 600 sophomores and seniors at Georgia Tech during the 1996-1997 and 2018-2019 academic years. Our objective was to study the evolution over two decades of: influences on student decision to study CHE, student vision of professional future after graduation, difficulty and interest in CHE major, student interests outside of CHE, student demographics, and student experiences outside the university.

Published
2022
Full Text
View/download PDF

8. Assessing the risk of a clinically significant infection from a Microneedle Array Patch (MAP) product

Author

Dul, Maria, Alali, Mohammed, Ameri, Mahmoud, Burke, Matthew Douglas, Craig, Christine M., Creelman, Benjamin Paul, Dick, Lisa, Donnelly, Ryan F., Eakins, Michael N., Frivold, Collrane, Forster, Angus Harry, Gilbert, Philippe-Alexandre, Henke, Stefan, Henry, Sebastien, Hunt, Desmond, Lewis, Hayley, Maibach, Howard I., Mistilis, Jessica Joyce, Park, Jung-Hwan, Prausnitz, Mark R., Robinson, David Kenneth, Hernandez, Carmen Amelia Rodriguez, Ross, Charles, Shin, Juyeop, Speaker, Tycho Joseph, Taylor, Kevin Michael, Zehrung, Darin, Birchall, James C., Jarrahian, Courtney, and Coulman, Sion A.

Published
2023
Full Text
View/download PDF

18. Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]

Author

Adigweme, Ikechukwu, Akpalu, Edem, Yisa, Mohammed, Donkor, Simon, Jarju, Lamin B., Danso, Baba, Mendy, Anthony, Jeffries, David, Njie, Abdoulie, Bruce, Andrew, Royals, Michael, Goodson, James L., Prausnitz, Mark R., McAllister, Devin, Rota, Paul A., Henry, Sebastien, and Clarke, Ed

Published
2022
Full Text
View/download PDF

20. Feasibility of engineered Bacillus subtilis for use as a microbiome‐based topical drug delivery platform.

Author

Montgomery, Veronica A., Wood‐Yang, Amy J., Styczynski, Mark P., and Prausnitz, Mark R.

Subjects
DRUG delivery systems, GREEN fluorescent protein, BACILLUS subtilis, PROTEIN models, TISSUE culture
Abstract

Non‐adherence to medication is a major challenge in healthcare that results in worsened treatment outcomes for patients. Reducing the frequency of required administrations could improve adherence but is challenging for topical drug delivery due to the generally short residence time of topical formulations on the skin. In this study, we sought to determine the feasibility of developing a microbiome‐based, long‐acting, topical delivery platform using Bacillus subtilis for drug production and delivery on the skin, which was assessed using green fluorescent protein as a model heterologous protein for delivery. We developed a computational model of bacteria population dynamics on the skin and used its qualitative predictions to guide experimental design choices. Using an ex vivo pig skin model and a human skin tissue culture model, we saw persistence of delivered bacteria for multiple days and observed little evidence of cytotoxicity to human keratinocyte cells in vitro. Finally, using an in vivo mouse model, we found that the delivered bacteria persisted on the skin for at least 1 day during every‐other‐day application and did not appear to present safety concerns. Taken together, our results support the feasibility of using engineered B. subtilis for topical drug delivery. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Tolerability of a piezoelectric microneedle electroporator in human subjects.

Author

Lu, Chao‐Yi, Rohilla, Pankaj, Felner, Eric I., Byagathvalli, Gaurav, Azizoglu, Erkan, Bhamla, M. Saad, and Prausnitz, Mark R.

Subjects
HYPODERMIC needles, DNA vaccines, ELECTRIC fields, IMMUNE response, RNA, ELECTROPORATION, NEURAL stimulation
Abstract

Electroporation, or the use of electric pulses to facilitate the intracellular delivery of DNA, RNA, and other molecules, is a well‐established technique, that has been demonstrated to significantly augment the immunogenicity of DNA/mRNA vaccines and therapeutics. However, the clinical translation of traditional electroporators has been limited due to high costs, large size, complex user operation, and poor tolerability in humans due to nerve stimulation. In prior work, we introduced ePatch: an ultra‐low‐cost, handheld, battery‐free electroporator employing a piezoelectric pulser coupled with a microneedle electrode array that showed enhanced immunogenic responses to an intradermal SARS‐CoV‐2 DNA vaccine in mice. The current study shifts focus from efficacy to tolerability, hypothesizing that ePatch's microneedle array, which localizes the electric field to the superficial skin strata, will minimize nerve stimulation and improve patient comfort. We tested this hypothesis in 14 healthy adults, monitoring pain and other potential adverse effects associated with electroporation. Compared to the insertion of a traditional hypodermic needle, the ePatch was less painful. Adverse effects such as pain, tenderness, erythema and swelling at the application sites were minimal, transient, and statistically indistinguishable between the experimental and placebo ePatch application, suggesting excellent tolerability towards electroporation. In summary, ePatch has a favorable tolerability profile in humans and offers the potential for the safe use of electroporation in a variety of clinical settings, including DNA and mRNA vaccination. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial

Author

Rouphael, Nadine G., Lai, Lilin, Tandon, Sonia, McCullough, Michele Paine, Kong, Yunchuan, Kabbani, Sarah, Natrajan, Muktha S., Xu, Yongxian, Zhu, Yerun, Wang, Dongli, O’Shea, Jesse, Sherman, Amy, Yu, Tianwei, Henry, Sebastien, McAllister, Devin, Stadlbauer, Daniel, Khurana, Surender, Golding, Hana, Krammer, Florian, Mulligan, Mark J., and Prausnitz, Mark R.

Published
2021
Full Text
View/download PDF

49. Ultrasound-Enhanced Drug Transport and Distribution in the Brain

Author

Liu, Ying, Paliwal, Sumit, Bankiewicz, Krystof S., Bringas, John R., Heart, Gill, Mitragotri, Samir, and Prausnitz, Mark R.

Subjects
Biomedicine, Pharmacy, Biochemistry, general, Biotechnology, Pharmacology/Toxicology, brain tumor, chemotherapy, drug delivery, therapeutic ultrasound, tissue permeability
Abstract

Drug delivery in the brain is limited by slow drug diffusion in the brain tissue. This study tested the hypothesis that ultrasound can safely enhance the permeation of drugs in the brain. In vitro exposure to ultrasound at various frequencies (85 kHz, 174 kHz, and 1 MHz) enhanced the permeation of tritium-labeled molecules with molecular weight up to 70 kDa across porcine brain tissue. A maximum enhancement of 24-fold was observed at 85 kHz and 1,200 J/cm2. In vivo exposure to 1-MHz ultrasound further demonstrated the ability of ultrasound to facilitate molecule distribution in the brain of a non-human primate. Finally, ultrasound under conditions similar to those used in vivo was shown to cause no damage to plasmid DNA, siRNA, adeno-associated virus, and fetal rat cortical neurons over a range of conditions. Altogether, these studies demonstrate that ultrasound can increase drug permeation in the brain in vitro and in vivo under conditions that did not cause detectable damage.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results